NCT05681273 is a Phase 1 clinical trial of Chiglitazar in T2DM, sponsored by Chipscreen Biosciences, Ltd..

Who is sponsoring NCT05681273?

NCT05681273 is sponsored by Chipscreen Biosciences, Ltd..

What drugs are being tested in NCT05681273?

Interventions in NCT05681273: Chiglitazar, Empagliflozin, Atorvastatin, Valsartan.

Is NCT05681273 still recruiting?

NCT05681273 is currently completed. Last updated 15 June 2023.

Last reviewed 2023-06-15 · How we verify

NCT05681273

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

Completed Phase 1 Last updated 15 June 2023

What this trial tests

Phase 1 trial testing Chiglitazar in T2DM in 48 participants. Completed in 21 March 2023.

Timeline

17 February 2023

Primary endpoint
21 March 2023

21 March 2023

Quick facts

Lead sponsor	Chipscreen Biosciences, Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	17 February 2023
Primary completion	21 March 2023
Estimated completion	21 March 2023
Sites	1 location across China

Drugs / interventions tested

Chiglitazar — full drug profile →
Empagliflozin (empagliflozin) — full drug profile →
Atorvastatin (atorvastatin) — full drug profile →
Valsartan (VALSARTAN) — full drug profile →

Conditions studied

T2DM — all drugs for T2DM →

Sponsor

Chipscreen Biosciences, Ltd. — full company profile →

Who can join

Adults 18 to 45, any sex, with T2DM. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase 1 open label study is being conducted to characterize the pharmacokinetic (PK) and safety profiles of Chiglitazar with Empagliflozin，Atorvastatin and Valsartan in healthy subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Drug-Drug Interaction of Chiglitazar with Empagliflozin, Atorvastatin, and Valsartan: An Open-Label, Single-Center, Self-Control, 3-Period Study.
Sheng L, Li X, Yu J, Yang X, et al · · 2026 · PMID 42148367 · DOI 10.2147/dddt.s588573

Verify or expand the search:

Other trials of Chiglitazar

Trials testing the same drug.

NCT07303803 — A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus · Phase 2 · not yet recruiting
NCT06125587 — Chiglitazar/Metformin in Non-obese Women With PCOS · Phase 2, PHASE3 · completed
NCT05515445 — Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function · Phase 1 · completed
NCT05515458 — Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function · Phase 1 · completed

Other recruiting trials for T2DM

Currently open trials in the same condition.

NCT07347080 — A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) · EARLY_PHASE1 · recruiting
NCT07005362 — Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D · recruiting
NCT07019012 — Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients Wi · Phase 4 · recruiting
NCT06942195 — Effects of Calcium on Gut Functions and Blood Glucose in Humans With Type 2 Diabetes · NA · recruiting
NCT06686134 — Comprehensive Clinical Evaluation Study of GLP-1RA · recruiting

Other Chipscreen Biosciences, Ltd. trials

Trials by the same sponsor.

NCT07511010 — Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets · Phase 1 · not yet recruiting
NCT07519265 — Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets · NA · not yet recruiting
NCT07412015 — Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets · NA · not yet recruiting
NCT07445295 — Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenoca · Phase 3 · not yet recruiting
NCT07129382 — A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05681273 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chipscreen Biosciences, Ltd.
Last refreshed: 15 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05681273.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing